Pfizer signs agreement to allow broader global access to its experimental Covid-19 antiviral pill

The agreement with the Medicines Patent Pool, a United Nations-backed public health organization, would allow generic manufacturers to make the pill widely available in 95 low- and middle-income countries covering 53% of the world's population, the company said.

 

The pill, known as PF-07321332 or Paxlovid, is to be given in combination with an older antiviral drug called ritonavir. ...

 

ALSO SEE: Pfizer to conduct trials of antiviral COVID-19 pill in Russia